Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 1;38(4):239-244.
eCollection 2019 Dec.

Fatigue in myotonic dystrophy type 1: a seven-year prospective study

Stojan Peric  1 , Bogdan Bjelica  1 , Ivo Bozovic  1 , Jovan Pesovic  2 , Teodora Paunic  1 , Marija Banovic  1 , Milos Brkusanin  2 , Ksenija Aleksic  1 , Ivana Basta  1 , Dusanka Savic Pavicevic  2 , Vidosava Rakocevic Stojanovic  1
Affiliations

Fatigue in myotonic dystrophy type 1: a seven-year prospective study

Stojan Peric et al. Acta Myol. .

Abstract

Objectives: Cross-sectional studies reported fatigue in 50-90% of patients with myotonic dystrophy type 1 (DM1). The aim of this research was to assess frequency of fatigue in DM1 patients during a seven-year period.

Materials and methods: Study included 64 DM1 patients at baseline (50% males, age 42 ± 12 years), and 38 after seven years. Following scales were used: Muscular Impairment Rating Scale (MIRS), Fatigue Severity Scale (FSS, score equal to or greater than 36 indicates significant fatigue), and Daytime Sleepiness Scale (DSS, score of more than six is considered significant).

Results: At baseline, 54% of DM1 patients had fatigue and 46% had excessive daytime sleepiness (EDS). Ten (32%) patients with fatigue had no EDS. At the baseline, patients with fatigue were older, were more likely to had adult-onset DM1, worse MIRS and DSS compared to the patients without fatigue. After seven years, FSS score increased (34 ± 15 vs 48 14, p < 0.01), fatigue was found in 82% of patients, and EDS in 60%. Still eight (26%) patients with fatigue had no EDS. Fatigue progression did not parallel MIRS increase.

Conclusions: Fatigue is a common symptom of DM1 and its progression during time did not correlate with the progression of muscle weakness.

Keywords: fatigue; follow-up; myotonic dystrophy type 1; sleepiness; weakness.

PubMed Disclaimer

References

    1. Brook JD, Mc Currach ME, Harley Hg, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member. Cell 1992;69:385. - PubMed
    1. Emery AE. Population frequencies of inherited neuromuscular diseases – A world survey. Neuromuscular Disord 1991;1:19-29. - PubMed
    1. Wenninger S, Montagnese F, Schoser B. Core clinical phenotypes in myotonic dystrophies. Front Neurol 2018;9:303. - PMC - PubMed
    1. Kalkman JS, Schillings ML, van der Werf SP, et al. Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I. J Neurol Neurosurg Psychiatry 2005;76:1406-9. - PMC - PubMed
    1. Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve 2007;36:294-306. - PubMed

LinkOut - more resources